News
Latest News
Cost Recovery Implementation Statement (CRIS) - Regulation of Medicinal Cannabis 2021-22
9 September 2021
Provides information on how the Office of Drug Control implements cost recovery for regulatory activities.
Testing of cannabis, cannabis resin and products manufactured from cannabis and cannabis resin
26 August 2021
Guidance note for 'Testing of cannabis and cannabis resin' updated.
Enactment of the Narcotic Drugs Amendment (Medicinal Cannabis) Act 2021
7 July 2021
The Amendment Act provides for amendments to the Narcotic Drugs Act 1967 to support an innovative Australian medicinal cannabis industry for the benefit of Australian patients.
Australian Government response to the Senate Community Affairs References Committee report: Inquiry into Current barriers to patient access to medicinal cannabis in Australia
4 March 2021
The Australian Government response to the Inquiry into current barriers to patient access to medicinal cannabis has now been published
Introduction of the Narcotic Drugs Amendment (Medicinal Cannabis) Bill 2021
4 February 2021
Introduction of the Narcotic Drugs Amendment (Medicinal Cannabis) Bill 2021
Commission on Narcotic Drugs votes on recommendations for cannabis and cannabis related substances
10 December 2020
On 2 December 2020, Australia voted at the Commission on Narcotic Drugs on six recommendations concerning the scheduling of cannabis and cannabis related substances
Medicinal cannabis permit reform consultation
13 November 2020
The ODC is seeking comments on a review of the structure, design and administrative processes relating to medicinal cannabis related permits
Commencement of fees and charges for cannabis-related manufacture
2 November 2020
Cost recovery arrangements for cannabis-related manufacture licences and permits commenced on 1 November 2020.
Increasing consumer access to kava
7 October 2020
The Australian Government will implement a second phase of the pilot program to increase the amount of kava allowed to be imported in Australia.
Introduction of fees and charges for cannabis-related manufacture
6 October 2020
From 1 November 2020, subject to formal approval from the Federal Executive Council, cost recovery arrangements will be extended to cannabis-related manufacture licences and permits under the Medicinal Cannabis Scheme.